Roles of N-methyl-D-aspartate receptors and D-amino acids in cancer cell viability

Siqi Du1, Yu-Sheng Sung1, Michael Wey1

  • 1Department of Chemistry and Biochemistry, University of Texas at Arlington, Arlington, TX, 76019, USA.

Molecular Biology Reports
|September 6, 2020
PubMed

Insights

N-methyl-D-aspartate (NMDA) receptor antagonists inhibit skin cancer growth. However, specific D-amino acids can reverse this effect, suggesting a novel therapeutic approach targeting D-amino acid pathways in cancer.

Area of Science:

  • Oncology
  • Neuroscience
  • Biochemistry

Background:

  • N-methyl-D-aspartate (NMDA) receptors are upregulated in various cancers, influencing tumor growth.
  • NMDA receptor antagonists show potential in cancer therapy by affecting cell viability.
  • Elevated D-amino acid levels are observed in cancer cells.

Purpose of the Study:

  • To investigate the role of NMDA receptors and D-amino acids in human skin cancer.
  • To explore the potential of targeting NMDA receptors and D-amino acid pathways for anticancer therapy.

Main Methods:

  • Comparative study of human skin cancer (Hs 895.T) and normal (Hs 895.Sk) cell lines.
  • Treatment with NMDA receptor channel blockers (MK-801, memantine).
  • Assessment of D-amino acid (D-Ser, D-Ala, D-Asp) reversal effects and intracellular amino acid composition changes.

Main Results:

  • NMDA receptor expression confirmed in both skin cell lines.
  • MK-801 and memantine inhibited skin cell growth by reducing NMDA receptor activity.
  • D-amino acids reversed the antiproliferative effects of MK-801 and memantine.
  • Skin cancer cells showed selectively elevated intracellular D-amino acids upon MK-801 exposure.

Conclusions:

  • Upregulated D-amino acids can counteract drug-induced antiproliferative effects in skin cancer via NMDA receptor reactivation.
  • Targeting D-amino acid pathways presents a potential innovative anticancer therapeutic strategy.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.8K